Skip to main content

Table 1 Significant changes in TET2-target gene expression associated with prostate cancer development and progression

From: Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression

Gene Tumor vs normal1
Matched tumor and normal
Tumor vs normal1
All TCGA tumors
Recurrence1 Stage1 Gleason score (overall)2 GS6 vs GS73 GS6 vs GS8 +3 GS7 vs GS8 +3
ASB2 2.9543E−08 1.1163E−10 0.0189 0.0095 3.1843E−05 0.17 0.00044413 2.1003E−4
ETNK2 8.0425E−15 1.6991E−16 0.0147 0.3725 0.1526 1 0.4005 0.0924
KCNJ15 1.1797E−09 6.9856E−14 0.0436 0.6534 0.0842 0.4247 1 0.0487
MEIS2 8.6435E−09 1.4128E−13 0.0125 0.0256 0.0010 0.5208 0.0100 0.0015
NRG1 1.6456E−05 1.9533E−11 0.0013 0.0023 0.0016 1 0.0918 6.6543E−4
NTN1 3.1531E−05 1.1782E−07 0.0091 0.0261 0.0273 1 0.205 0.0139
NUDT10 2.4896E−08 2.8735E−10 0.0235 0.5739 0.4542 0.4667 0.3151 0.9259
PDE4A 2.1250E−09 1.2586E−12 0.0431 0.6292 0.5444 0.9831 1 0.4186
SRPX 1.0079E−05 3.2133E−08 0.0078 0.0014 1.1851E−07 1 0.0014 8.9930E−08
  1. Bolded and underlined numbers represent significant p values as derived from 1Mann-Whitney U test, 2Kruskal-Wallis test, and 3Bonferroni-adjusted Dunn test